Voyageur Pharmaceuticals Ltd.
VM.V
TSX
| 08/31/2024 | 05/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -38.71% | 72.18% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -38.68% | 72.08% | |||
| Operating Income | 38.68% | -72.08% | |||
| Income Before Tax | 36.41% | -68.42% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 36.41% | -68.42% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 36.41% | -68.42% | |||
| EBIT | 38.68% | -72.08% | |||
| EBITDA | 38.71% | -72.18% | |||
| EPS Basic | 36.67% | -66.67% | |||
| Normalized Basic EPS | 36.84% | -58.33% | |||
| EPS Diluted | 36.67% | -66.67% | |||
| Normalized Diluted EPS | 36.84% | -58.33% | |||
| Average Basic Shares Outstanding | 0.41% | 4.63% | |||
| Average Diluted Shares Outstanding | 0.41% | 4.63% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
